[sradman]

Why would spike binding matter for a protease inhibitor that works within the cell? Regardless, human kidney organoids with ACE2 receptors are available [1] so the question switches to why the human kidney organoid people don't coordinate with the GC376 drug makers for fast in-vitro experiments.

This is where the WHO and its member nation states should have stepped up. I'm assuming that I'm misunderstanding some fundamental aspect of the drug development process since Apeiron APN01 seemed like a promising potential treatment in April but it appears to have followed the status-quo human trial pace.

[1] https://www.cell.com/cell/pdf/S0092-8674(20)30399-8.pdf